genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2014
Acorda Therapeutics
News
Acorda Buys Civitas and Its Phase III PD Candidate for $525M
Drug Discovery
Up to $12M Deal Expands Acorda Offerings to Neuropathic Pain
Industry News
Bittersweet News at Biogen Idec
Drug Discovery
Acorda Wins $2.67M Army Contract for Spinal Cord Injury Drug Trial
Industry News
Acorda, Elan Wrap Up Their Deals
News
Simple Fixes that Entrepreneurs May Resist
Insights
Step Up for Biotechnology
Insights
People in the News
News
Acorda Licenses Phase II-Ready Brain and Spinal Cord Injury Candidate from Medtronic
News
Australia Approves Biogen Idec’s Fampyra for Improving Walking Ability in Multiple Sclerosis
1
2
3
Page 2 of 3
Scroll Up
Scroll Up
